Focal craniofacial hyperhidrosis associated with selective serotonin reuptake inhibitors

Rajaratnam, R.; Mehmi, M.; Lim, Seung-Woon; Lewis, Heather L.

doi:10.1111/j.1365-2230.2007.02486.x

Cited by 3 publications

(5 citation statements)

References 4 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[21] Disturbances of sweating (both hyper-and hypohidrosis) are listed as possible adverse effects of tricyclic antidepressants, and hyperhidrosis is listed as a possible adverse effect of selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors. [87,88] The serotonin antagonist antihistamine cyproheptadine was reported useful in treating SSRI-induced hyperhidrosis in a series of five patients. [89] The benzodiazepine clonazepam was useful in a single case of unilateral hyperhidrosis.…”

Section: Other Agentsmentioning

confidence: 99%

Treatment Options for Hyperhidrosis

Walling¹,

Swick

2011

American Journal of Clinical Dermatology

121

View full text Add to dashboard Cite

Hyperhidrosis is a disorder of excessive sweating beyond what is expected for thermoregulatory needs and environmental conditions. Primary hyperhidrosis has an estimated prevalence of nearly 3% and is associated with significant medical and psychosocial consequences. Most cases of hyperhidrosis involve areas of high eccrine density, particularly the axillae, palms, and soles, and less often the craniofacial area. Multiple therapies are available for the treatment of hyperhidrosis. Options include topical medications (most commonly aluminum chloride), iontophoresis, botulinum toxin injections, systemic medications (including glycopyrrolate and clonidine), and surgery (most commonly endoscopic thoracic sympathectomy [ETS]). The purpose of this article is to comprehensively review the literature on the subject, with a focus on new and emerging treatment options. Updated therapeutic algorithms are proposed for each commonly affected anatomic site, with practical procedural guidelines. For axillary and palmoplantar hyperhidrosis, topical treatment is recommended as first-line treatment. For axillary hyperhidrosis, botulinum toxin injections are recommended as second-line treatment, oral medications as third-line treatment, local surgery as fourth-line treatment, and ETS as fifth-line treatment. For palmar and plantar hyperhidrosis, we consider a trial of oral medications (glycopyrrolate 1-2 mg once or twice daily preferred to clonidine 0.1 mg twice daily) as second-line therapy due to the low cost, convenience, and emerging literature supporting their excellent safety and reasonable efficacy. Iontophoresis is considered third-line therapy for palmoplantar hyperhidrosis; efficacy is high although so are the initial levels of cost and inconvenience. Botulinum toxin injections are considered fourth-line treatment for palmoplantar hyperhidrosis; efficacy is high though the treatment remains expensive, must be repeated every 3-6 months, and is associated with pain and/or anesthesia-related complications. ETS is a fifth-line option for palmar hyperhidrosis but is not recommended for plantar hyperhidrosis due to anatomic risks. For craniofacial hyperhidrosis, oral medications (either glycopyrrolate or clonidine) are considered first-line therapy. Topical medications or botulinum toxin injections may be useful in some cases and ETS is an option for severe craniofacial hyperhidrosis.

show abstract

Section: Other Agentsmentioning

confidence: 99%

Treatment Options for Hyperhidrosis

Walling¹,

Swick

2011

American Journal of Clinical Dermatology

121

View full text Add to dashboard Cite

show abstract

“…16,17 Actually, this condition seems to be different from real unilateral or crossed LH. The stimulation of the peripheral nervous system by mucin deposits in the setting of poorly controlled hyperthyroiditis was speculated by Kato et al 18 It is debatable whether hyperthyroiditis was a causal factor or solely a coexistence in our case. In the first year of propylthiouracil therapy, there was still no change in sweating in the iodine-starch tests, but some thyroid tests including TSH and free T4 were still abnormal and hyperthyroiditis could not be controlled completely in spite of the therapy.…”

Section: Discussionmentioning

confidence: 66%

“…The stimulation of the peripheral nervous system by mucin deposits in the setting of poorly controlled hyperthyroiditis was speculated by Kato et al. 18 …”

Section: Discussionmentioning

confidence: 99%

“…It occurs very rarely on the body unilaterally or lesionally 3–17 . Occasionally, a craniofacial involvement occurs secondary to selective serotonin reuptake blockers 18 . These situations are different from eccrine nevi because of the existence of normal eccrine glands in the sweating areas.…”

Section: Introductionmentioning

confidence: 99%

“…[3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] Occasionally, a craniofacial involvement occurs secondary to selective serotonin reuptake blockers. 18 These situations are different from eccrine nevi because of the existence of normal eccrine glands in the sweating areas. LH involving only one side of the body is unilateral LH which may be caused by organic disorders, traumas or can be idiopathic.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Localized crossed hyperhidrosis and the coexistence of thyroid gland disease

Serdar¹,

Altunay

Yaşar³

et al. 2010

The Journal of Dermatology

View full text Add to dashboard Cite

Hyperhidrosis is the most common type of sweat gland disorder. It may be localized or generalized. The localized type usually occurs in a symmetrical fashion over the palms, soles and armpits as a response to emotional stimuli. Another form of the localized type is idiopathic localized unilateral hyperhidrosis which is very rare and the etiopathogenesis remains unclear. Here, we report a female patient who had localized crossed hyperhidrotic areas on her body (on the left side of the scalp, face and the shoulder and on the right side of the trunk) and also had thyroid gland disease. We herein discuss this extremely rare presentation of the disease and its association with thyroid gland disease.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2008

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Focal craniofacial hyperhidrosis associated with selective serotonin reuptake inhibitors

Cited by 3 publications

References 4 publications

Treatment Options for Hyperhidrosis

Treatment Options for Hyperhidrosis

Localized crossed hyperhidrosis and the coexistence of thyroid gland disease

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About